Takeda Pharmaceutical (TAK) Total Current Liabilities (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Total Current Liabilities of $17.3 billion for Q2 2026, up 15.67% year-over-year from $15.0 billion in Q2 2025, and down 3.96% quarter-over-quarter from $18.1 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Total Current Liabilities (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Total Current Liabilities history runs 10 years deep, the most recent figure standing at $17.3 billion for Q2 2026.
- In Q2 2026, Total Current Liabilities rose 15.67% year-over-year to $17.3 billion; the TTM figure through Jun 2026 stood at $17.3 billion (up 15.67% YoY), while the FY2026 annual figure was $18.8 billion, up 14.34% from the prior year.
- Total Current Liabilities for Q2 2026 stood at $17.3 billion, down from $18.1 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $18.8 billion in Q1 2023, with the low at $13.8 billion in Q4 2024.
- The 5-year median for Total Current Liabilities is $16.4 billion (2023), against an average of $16.5 billion.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities dropped 16.81% in 2024, then grew 22.9% in 2025.
- Takeda Pharmaceutical's Total Current Liabilities stood at $15.8 billion in 2022, then decreased by 2.49% to $15.4 billion in 2023, then slipped by 10.62% to $13.8 billion in 2024, then increased by 22.9% to $17.0 billion in 2025, then grew by 2.26% to $17.3 billion in 2026.
- Business Quant data shows TAK's Total Current Liabilities at $17.3 billion in Q2 2026, $18.1 billion in Q1 2026, and $17.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 1.79 Bn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 662.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.34 Bn |
| Mar 31, 2026 | 18.06 Bn |
| Dec 31, 2025 | 16.96 Bn |
| Sep 30, 2025 | 14.52 Bn |
| Jun 30, 2025 | 14.99 Bn |
| Mar 31, 2025 | 16.43 Bn |
| Dec 31, 2024 | 13.80 Bn |
| Sep 30, 2024 | 16.00 Bn |
| Jun 30, 2024 | 15.84 Bn |
| Mar 31, 2024 | 15.61 Bn |
| Dec 31, 2023 | 15.44 Bn |
| Sep 30, 2023 | 16.39 Bn |
| Jun 30, 2023 | 18.26 Bn |
| Mar 31, 2023 | 18.76 Bn |
| Dec 31, 2022 | 15.83 Bn |
| Sep 30, 2022 | 17.32 Bn |
| Jun 30, 2022 | 16.76 Bn |
| Mar 31, 2022 | 18.46 Bn |
| Dec 31, 2021 | 15.92 Bn |
| Sep 30, 2021 | 17.43 Bn |